InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

22 April, 2009

InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer.

Under the research collaboration with professor Jack Schalken (Laboratory of Experimental Urology), InteRNA’s unique lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer.

“We are very excited about this collaboration with professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of prostate cancer”, said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.

“Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis. Thus it is a truly symbiotic public-private partnership!”, said professor Jack Schalken of Radboud UNMC.